Mirum Pharmaceuticals Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Common Stock
August 12 2022 - 4:30PM
Business Wire
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a
biopharmaceutical company focused on the identification,
acquisition, development and commercialization of novel therapies
for debilitating rare and orphan diseases, today announced the
closing of its previously announced underwritten public offering of
4,000,000 shares of its common stock, including the exercise in
full by the underwriters of their option to purchase an additional
521,739 shares, at a price to the public of $23.00 per share. The
gross proceeds to Mirum from the offering, before deducting
underwriting discounts and commissions and offering expenses, were
$92.0 million.
J.P. Morgan, SVB Securities and Evercore ISI acted as joint
book-running managers for the offering. Raymond James acted as lead
manager for the offering.
The offering was made pursuant to a shelf registration statement
on Form S-3, including a base prospectus, that was previously filed
with the Securities and Exchange Commission (the “SEC”) and was
declared effective by the SEC on August 12, 2020. A preliminary
prospectus supplement and accompanying prospectus relating to the
offering were filed with the SEC and are available for free on the
SEC’s website located at http://www.sec.gov. A final prospectus
supplement and accompanying prospectus relating to the offering
were filed with the SEC and are available for free on the SEC’s
website located at http://www.sec.gov. Copies of the final
prospectus supplement and the accompanying prospectus relating to
the offering may be obtained from:
J.P. Morgan Securities LLC, Attention: Broadridge Financial
Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by email at
prospectus-eq_fi@jpmchase.com or by phone at (866) 803-9204; SVB
Securities LLC, Attention: Syndicate Department, 53 State Street,
40th Floor, Boston, MA 02109, by email at
syndicate@svbsecurities.com or by phone at (800) 808-7525, ext.
6105; or Evercore Group L.L.C., Attention: Equity Capital Markets,
55 East 52nd Street, New York, NY 10055, by email at
ecm.prospectus@evercore.com or by phone at (888) 474-0200.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy, nor shall there be any sale of,
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company
dedicated to transforming the treatment of rare liver diseases.
Mirum’s approved medication is LIVMARLI® (maralixibat) oral
solution which is approved in the U.S. for the treatment of
cholestatic pruritus in patients with Alagille syndrome one year of
age and older.
Mirum’s late-stage pipeline includes two investigational
treatments for debilitating liver diseases affecting children and
adults. LIVMARLI, an oral ileal bile acid transporter (IBAT)
inhibitor, is currently being evaluated in clinical trials for
pediatric liver diseases and includes the MARCH Phase 3 clinical
trial for progressive familial intrahepatic cholestasis (PFIC) and
the EMBARK Phase 2b clinical trial for patients with biliary
atresia. In addition, Mirum has an expanded access program open
across multiple countries for eligible patients with ALGS and
PFIC.
Mirum has submitted a Marketing Authorization Application to the
European Medicines Agency for LIVMARLI for the treatment of
cholestasis in patients with Alagille syndrome.
Mirum’s second investigational treatment, volixibat, an oral
IBAT inhibitor, is being evaluated in three potentially
registrational studies including the VISTAS Phase 2b clinical trial
for adults with primary sclerosing cholangitis, the OHANA Phase 2b
clinical trial for pregnant women with intrahepatic cholestasis of
pregnancy, and the VANTAGE Phase 2b clinical trial for adults with
primary biliary cholangitis.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220812005406/en/
Investor Contacts: Ian Clements, Ph.D.
investors@mirumpharma.com
Sam Martin Argot Partners ir@mirumpharma.com
Media Contact: Erin Murphy media@mirumpharma.com
Mirum Pharmaceuticals (NASDAQ:MIRM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Mirum Pharmaceuticals (NASDAQ:MIRM)
Historical Stock Chart
From Apr 2023 to Apr 2024